These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 31606539)

  • 1. Commentary on the Benefits of US Pharmacopeial Standards: A Generic Pharmaceutical Industry Survey.
    Warthin IK; Berik J; Podolsky D; Raghavendran V; Reddy R; Chang J; Porter N; Garito N
    J Pharm Sci; 2020 Feb; 109(2):944-949. PubMed ID: 31606539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs.
    Murimi-Worstell IB; Ballreich JM; Seamans MJ; Alexander GC
    PLoS One; 2019; 14(11):e0225109. PubMed ID: 31714946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Value of U.S. Pharmacopeial Standards: A Review of the Literature.
    Heyward J; Padula W; Tierce JC; Alexander GC
    J Pharm Sci; 2018 Oct; 107(10):2611-2617. PubMed ID: 29908148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competition And Vulnerabilities In The Global Supply Chain For US Generic Active Pharmaceutical Ingredients.
    Socal MP; Ahn K; Greene JA; Anderson GF
    Health Aff (Millwood); 2023 Mar; 42(3):407-415. PubMed ID: 36791331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of simvastatin tablets from the US and international markets obtained via the Internet.
    Veronin MA; Nguyen NT
    Ann Pharmacother; 2008 May; 42(5):613-20. PubMed ID: 18413690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality Testing of Difficult-to-Make Prescription Pharmaceutical Products Marketed in the US.
    Fisher AC; Viehmann A; Ashtiani M; Friedman RL; Buhse L; Kopcha M; Woodcock J
    JAMA Netw Open; 2020 Aug; 3(8):e2013920. PubMed ID: 32833019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
    Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
    BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
    Li DG; Joyce C; Mostaghimi A
    JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Countries Manufacturing Pharmaceuticals for the US Market: A 10-Year Analysis of Public Data.
    Hatton RC; Leighton G; Englander L
    Ann Pharmacother; 2022 Oct; 56(10):1106-1112. PubMed ID: 35040353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated trends in US brand-name and generic drug competition.
    Grabowski H; Long G; Mortimer R; Boyo A
    J Med Econ; 2016 Sep; 19(9):836-44. PubMed ID: 27064194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacopeial Standards for the Quality Control of Botanical Dietary Supplements in the United States.
    Sarma N; Upton R; Rose U; Guo DA; Marles R; Khan I; Giancaspro G
    J Diet Suppl; 2023; 20(3):485-504. PubMed ID: 34699287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generic medicines: issues and relevance for global health.
    Rana P; Roy V
    Fundam Clin Pharmacol; 2015 Dec; 29(6):529-42. PubMed ID: 26405851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Community pharmacists' understanding and perceptions of FDA therapeutic equivalence standards.
    Euen BJ; Fadda HM
    Res Social Adm Pharm; 2019 Jan; 15(1):77-83. PubMed ID: 29567088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies That Delay Market Entry of Generic Drugs.
    Vokinger KN; Kesselheim AS; Avorn J; Sarpatwari A
    JAMA Intern Med; 2017 Nov; 177(11):1665-1669. PubMed ID: 28975217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How drug life-cycle management patent strategies may impact formulary management.
    Berger J; Dunn JD; Johnson MM; Karst KR; Shear WC
    Am J Manag Care; 2016 Oct; 22(16 Suppl):S487-S495. PubMed ID: 28719222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the safety of generic drugs.
    Dighe SV
    Transplant Proc; 1999 May; 31(3A Suppl):23S-24S. PubMed ID: 10330955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entry decisions in the generic pharmaceutical industry.
    Morton FM
    Rand J Econ; 1999; 30(3):421-40. PubMed ID: 10558596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.